Ann: Trading Halt, page-38

Thanks, let's hope so.

She's in that area of neuroscience and saw a presentation at a conference. As far as exposure goes, there doesn't appear to be much from what I can see. There may be some within the medical research world from scientists in that area but otherwise it appears to be under the radar completely which may explain the low market cap. It's also worth noting that MSA and Huntingtons are niche areas to be in and don't get anywhere near the level of exposure as say cancer drugs, or the funding whether it be private or public.

Indeed, if it comes off I'll be paying for our next holiday for sure!